Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure (SELLIFA)
Primary Purpose
Liver Failure, Critical Illness
Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
Parenteral nutrition
Enteral nutrition
Sponsored by
About this trial
This is an interventional treatment trial for Liver Failure focused on measuring Liver failure, Liver cirrhosis, Parenteral nutrition, Enteral nutrition, Lipids, Safety, Drug tolerance
Eligibility Criteria
Inclusion Criteria:
- All consecutive patients with a diagnosis of chronic liver failure;
- Planned total nutritional support;
- Adult patient aged 18 years or above, and less than 85;
- Admission to the ICU for an expected period of > 24 hours;
- Informed consent of the patient or nearest relative.
Exclusion Criteria:
- Absolute contra-indications to enteral nutrition : total mechanical ileus, persistent vomiting, high output fistulas, uncertain gastrointestinal anastomosis;
- Absolute contra-indications to parenteral nutrition : severe hypertriglyceridemia > 6 mmol/l (> 545 mg/dL), severe diabetic ketoacidosis;
- Age less than 18 years or more than 85;
- Pregnancy, including HELLP syndrome;
- Active malignancy with metastases (localized hepatocellular carcinoma is not an exclusion criteria);
- Systemic chemotherapy in the last 4 weeks (trans-arterial chemo-embolisation for localized hepatocellular carcinoma is not an exclusion criteria);
- Acquired immunodeficiency syndrome and antiretroviral therapy;
- Refusal of the patient or nearest relative.
Sites / Locations
- Departement of intensive care, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Parenteral nutrition
Enteral nutrition
Outcomes
Primary Outcome Measures
Change in plasma concentration of triglycerides, total cholesterol, HDL-cholesterol, free fatty acids, apolipoproteins, lipoprotein (a)
Secondary Outcome Measures
Incidence of hyperglycaemia
Alteration of liver function
Gastrointestinal intolerance
Gastrointestinal bleeding
Septic complications
Occurence of new organ dysfunction
Length of stay in the intensive care unit (ICU)
Mortality
Full Information
NCT ID
NCT00522730
First Posted
August 29, 2007
Last Updated
September 2, 2009
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
1. Study Identification
Unique Protocol Identification Number
NCT00522730
Brief Title
Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure
Acronym
SELLIFA
Official Title
Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
August 2007 (undefined)
Primary Completion Date
August 2009 (Actual)
Study Completion Date
August 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to determine the tolerance on lipid metabolism and the safety of short-term parenteral nutrition as compared to enteral nutrition in critically ill patients with liver failure.
Detailed Description
An impaired lipid metabolism is often found in patients with liver disease and is assumed to influence the prognosis. The central role of lipid metabolism in the pathophysiology of fatty liver disease and steatohepatitis is well established. In cirrhotic patients, serum lipid levels are mostly decreased and related to the severity of liver failure; in addition, the structure and composition of lipoproteins differ from that of healthy individuals. A reduction in high-density lipoproteins has been associated with higher cytokines levels and a poorer clinical outcome in septic patients. Furthermore, the oxidative stress induced by septic complications in critically ill patients with liver failure may lead to further hepatocellular injury and activation of systemic inflammation cascade.
In this setting, the influence of nutrition on lipid metabolism may have an impact on the severity of liver failure and associated complications. Although plasma clearance and oxidation of lipids were considered to be normal in the majority of patients with cirrhosis, most previous studies only reported the effects of an oral ingestion or parenteral infusion of lipids during a few hours.
The present randomized controlled trial will be conducted in a subgroup of patients enrolled in the SELLIFA-01 prospective study (NCT00488917). The purpose of the nutritional trial is to determine the tolerance on lipid metabolism and the safety of isocaloric short-term parenteral nutrition as compared to enteral nutrition in critically ill septic and non septic patients with liver failure. The nutrition will be delivered continuously for 5 days and will provide a daily energy supply corresponding to current resting energy expenditure as determined by indirect calorimetry, with 35% of total energy requirements as lipids, 15% as proteins (maximum 1.2g/kg ideal body weight/day), and 50% as dextrose. A tight glucose control strategy will be implemented to avoid hyperglycemia.
The trial is designed to randomly assign 15 patients in each interventional group in order to detect more than 25% increase in plasma triglycerides levels with 80% statistical power for two-tailed type I error of 5%.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Failure, Critical Illness
Keywords
Liver failure, Liver cirrhosis, Parenteral nutrition, Enteral nutrition, Lipids, Safety, Drug tolerance
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Parenteral nutrition
Arm Title
2
Arm Type
Active Comparator
Arm Description
Enteral nutrition
Intervention Type
Other
Intervention Name(s)
Parenteral nutrition
Intervention Description
Duration : 5 days
Intervention Type
Other
Intervention Name(s)
Enteral nutrition
Intervention Description
Duration : 5 days
Primary Outcome Measure Information:
Title
Change in plasma concentration of triglycerides, total cholesterol, HDL-cholesterol, free fatty acids, apolipoproteins, lipoprotein (a)
Time Frame
within 5 days
Secondary Outcome Measure Information:
Title
Incidence of hyperglycaemia
Time Frame
within 5 days
Title
Alteration of liver function
Time Frame
within 5 and 28 days
Title
Gastrointestinal intolerance
Time Frame
within 5 days
Title
Gastrointestinal bleeding
Time Frame
within 5 and 28 days
Title
Septic complications
Time Frame
within 5 and 28 days
Title
Occurence of new organ dysfunction
Time Frame
within 5 and 28 days
Title
Length of stay in the intensive care unit (ICU)
Time Frame
within 5 and 28 days
Title
Mortality
Time Frame
within 5 and 28 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All consecutive patients with a diagnosis of chronic liver failure;
Planned total nutritional support;
Adult patient aged 18 years or above, and less than 85;
Admission to the ICU for an expected period of > 24 hours;
Informed consent of the patient or nearest relative.
Exclusion Criteria:
Absolute contra-indications to enteral nutrition : total mechanical ileus, persistent vomiting, high output fistulas, uncertain gastrointestinal anastomosis;
Absolute contra-indications to parenteral nutrition : severe hypertriglyceridemia > 6 mmol/l (> 545 mg/dL), severe diabetic ketoacidosis;
Age less than 18 years or more than 85;
Pregnancy, including HELLP syndrome;
Active malignancy with metastases (localized hepatocellular carcinoma is not an exclusion criteria);
Systemic chemotherapy in the last 4 weeks (trans-arterial chemo-embolisation for localized hepatocellular carcinoma is not an exclusion criteria);
Acquired immunodeficiency syndrome and antiretroviral therapy;
Refusal of the patient or nearest relative.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre-François Laterre, MD
Organizational Affiliation
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Yvan Fleury, MD
Organizational Affiliation
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Official's Role
Principal Investigator
Facility Information:
Facility Name
Departement of intensive care, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
12. IPD Sharing Statement
Learn more about this trial
Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure
We'll reach out to this number within 24 hrs